These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Harnessing NK Cells for Cancer Treatment. Minetto P; Guolo F; Pesce S; Greppi M; Obino V; Ferretti E; Sivori S; Genova C; Lemoli RM; Marcenaro E Front Immunol; 2019; 10():2836. PubMed ID: 31867006 [TBL] [Abstract][Full Text] [Related]
3. Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? Ben-Shmuel A; Biber G; Barda-Saad M Front Immunol; 2020; 11():275. PubMed ID: 32153582 [TBL] [Abstract][Full Text] [Related]
5. Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer. Mercogliano MF; Bruni S; Elizalde PV; Schillaci R Front Oncol; 2020; 10():584. PubMed ID: 32391269 [TBL] [Abstract][Full Text] [Related]
6. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints. Hargadon KM Clin Transl Med; 2020 Jan; 10(1):374-411. PubMed ID: 32508018 [TBL] [Abstract][Full Text] [Related]
7. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes. Pesce S; Trabanelli S; Di Vito C; Greppi M; Obino V; Guolo F; Minetto P; Bozzo M; Calvi M; Zaghi E; Candiani S; Lemoli RM; Jandus C; Mavilio D; Marcenaro E Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255582 [TBL] [Abstract][Full Text] [Related]
8. Immunological Approaches Towards Cancer and Inflammation: A Cross Talk. Qu X; Tang Y; Hua S Front Immunol; 2018; 9():563. PubMed ID: 29662489 [TBL] [Abstract][Full Text] [Related]
9. Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer. Nersesian S; Glazebrook H; Toulany J; Grantham SR; Boudreau JE Front Immunol; 2019; 10():1782. PubMed ID: 31456796 [TBL] [Abstract][Full Text] [Related]
10. Diversity of immune checkpoints in cancer immunotherapy. Guo Z; Zhang R; Yang AG; Zheng G Front Immunol; 2023; 14():1121285. PubMed ID: 36960057 [TBL] [Abstract][Full Text] [Related]
11. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells. Kim N; Kim HS Front Immunol; 2018; 9():2041. PubMed ID: 30250471 [TBL] [Abstract][Full Text] [Related]
16. Association of Germline Variants in Natural Killer Cells With Tumor Immune Microenvironment Subtypes, Tumor-Infiltrating Lymphocytes, Immunotherapy Response, Clinical Outcomes, and Cancer Risk. Xu X; Li J; Zou J; Feng X; Zhang C; Zheng R; Duanmu W; Saha-Mandal A; Ming Z; Wang E JAMA Netw Open; 2019 Sep; 2(9):e199292. PubMed ID: 31483464 [TBL] [Abstract][Full Text] [Related]
17. Tumor immunotherapy: New aspects of natural killer cells. Li Y; Sun R Chin J Cancer Res; 2018 Apr; 30(2):173-196. PubMed ID: 29861604 [TBL] [Abstract][Full Text] [Related]
19. Normal human CD4(+) helper T cells express Kv1.1 voltage-gated K(+) channels, and selective Kv1.1 block in T cells induces by itself robust TNFα production and secretion and activation of the NFκB non-canonical pathway. Fellerhoff-Losch B; Korol SV; Ganor Y; Gu S; Cooper I; Eilam R; Besser M; Goldfinger M; Chowers Y; Wank R; Birnir B; Levite M J Neural Transm (Vienna); 2016 Mar; 123(3):137-57. PubMed ID: 26611796 [TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Sasidharan Nair V; Elkord E Immunol Cell Biol; 2018 Jan; 96(1):21-33. PubMed ID: 29359507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]